Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArtryaASX:AYA +0.75%24 EV-to-EBIT is -22.96 as of Aug. 01, 2026. GuruFocus rates ASX:AYA with a GF Score™ of 24/100. Among 471 Healthcare Providers & Services companies, Artrya ranks worse than 212314.01% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Artrya's Enterprise Value is A$582.99 Mil.
Artrya's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-25.39 Mil. Therefore, Artrya's EV-to-EBIT for today is -22.96.
The historical rank and industry rank for Artrya's EV-to-EBIT or its related term are showing as below:
ASX:AYA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -33.34 Med: 0 Max: 0
Current: -22.96
ASX:AYA's EV-to-EBIT is ranked worse than 100% of 471
companies
in the Healthcare Providers & Services industry
Industry Median: 15.84
vs ASX:AYA: -22.96
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Artrya's Enterprise Value for the quarter that ended in Dec. 2025 was A$668.36 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Artrya's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-25.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artrya EV-to-EBIT Related Terms
Artrya EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Artrya's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Artrya's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artrya EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Artrya's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Artrya's EV-to-EBIT falls into.
Artrya's current Enterprise Value is A$582.99 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Artrya's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-25.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artrya (ASX:AYA) has a EV-to-EBIT of -22.96 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Artrya and its competitors. According to the industry distribution chart, Artrya ranks #999999 out of 471 companies in the Healthcare Providers & Services industry.
Is Artrya's EV-to-EBIT too high?
Artrya's current EV-to-EBIT is -22.96. Based on the distribution chart, Artrya ranks #999999 out of 471 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Artrya has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Artrya's EV-to-EBIT compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Artrya ranks #999999 out of 471 companies for EV-to-EBIT. This places Artrya in the lower half of its industry. The industry median EV-to-EBIT is 15.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Artrya and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artrya's current EV-to-EBIT is -22.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artrya stock overvalued right now?
Artrya (ASX:AYA) has a current EV-to-EBIT of -22.96. The current EV-to-EBIT is -22.96. Artrya's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Artrya (ASX:AYA), the current EV-to-EBIT is -22.96 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artrya Ltd is a medical technology company. The company is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. It is managed based on a single segment, being the development of AI-driven CCTA image analysis technology.
24GF Score
Get the complete analysis for ASX:AYA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AYA has been successfully added to your 
